Related Experiment Video
Updated: Jan 20, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis
Massimo Acquaviva1, Claudia Bassani1, Nicole Sarno1
1Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.
Abstract:
Recent evidence suggests that the primary progressive form of multiple sclerosis (PP-MS) may present with specific immunological alterations. In this study we focused our attention on CD161, an NK and T cell marker upregulated in relapsing-remitting MS, and investigated its transcript and protein levels in blood cells from PP-MS and healthy individuals. We demonstrated transcriptional downregulation of CD161 in PP-MS and described concomitant mRNA reduction for RORgt, CCR6, CXCR6, KLRK1/NKG2D and many other markers typical of mucosa associated invariant T (MAIT) cells. Targeted multiparametric flow cytometry on fresh blood cells from an independent cohort of case-control subjects confirmed the selective loss of circulating CD8 CD161high T cells, which consist mainly of MAIT cells, and not of CD8 CD161int T cells in PP-MS. These data demonstrate alterations in a specific circulating immune cell subset in MS patients with progressive onset.
Related Concept Videos
08:11Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
09:41Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
11:35The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
08:18A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:48Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
06:42Real-Time In Vitro Migration Assay for Primary Murine CD8+ T Cells

